loading page

Central high mobility group box-1 induces mechanical hypersensitivity with spinal microglial activation in a mouse model of hemi-Parkinson's disease
  • +7
  • Fumiaki Sato,
  • Yoki Nakamura,
  • Simeng Ma,
  • Takahiro Kochi,
  • Kazue Hisaoka-Nakashima,
  • Dengli Wang,
  • Keyue Liu,
  • Hidenori Wake,
  • Masahiro Nishibori,
  • Norimitsu Morioka
Fumiaki Sato
Hiroshima University Graduate School of Biomedical & Health Sciences
Author Profile
Yoki Nakamura
Hiroshima University Graduate School of Biomedical & Health Sciences
Author Profile
Simeng Ma
Hiroshima University Graduate School of Biomedical & Health Sciences
Author Profile
Takahiro Kochi
Hiroshima University Graduate School of Biomedical & Health Sciences
Author Profile
Kazue Hisaoka-Nakashima
Hiroshima University Graduate School of Biomedical & Health Sciences
Author Profile
Dengli Wang
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Author Profile
Keyue Liu
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Author Profile
Hidenori Wake
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Author Profile
Masahiro Nishibori
Okayama University Graduate School of Medicine and Dentistry
Author Profile
Norimitsu Morioka
Hiroshima University Graduate School of Biomedical & Health Sciences

Corresponding Author:[email protected]

Author Profile

Abstract

Background and Purpose: Parkinson’s disease (PD) patients often complain of pain, but this problem has been neglected and is poorly understood. High mobility group box-1 (HMGB1), an alarmin/damage-associated molecular patterns protein, is increased in the cerebrospinal fluid in PD patients. However, little is known of the relationship between HMGB1 and pain associated with PD. Here, we investigated the role of central HMGB1 in the regulation of nociceptive hypersensitivity in a mouse model of PD. Experimental Approach: Male ddY mice were microinjected unilaterally with 6-hydroxydopamine (6OHDA) into the striatum. These hemi-PD mice were treated with anti-HMGB1 neutralizing antibody (nAb; 10 µg in 10 µL) by intranasal (i.n.) administration. The mechanical hypersensitivity of the hind paws was evaluated with the von Frey test. Spinal microglial activity was analyzed by immunostaining for ionized calcium-binding adapter molecule 1. Key Results: The 6OHDA-administered mice displayed unilateral loss of dopamine neurons in the substantia nigra and mechanical hypersensitivity in both hind paws. Moreover, spinal microglia were activated in these hemi-PD mice. Twenty-eight days after the 6OHDA injections, repeated i.n., but not systemic, treatment with anti-HMGB1 nAb inhibited the bilateral mechanical hypersensitivity and spinal microglial activation. However, the anti-HMGB1 nAb did not ameliorate the dopamine neuron loss. Moreover, intracerebroventricular injection with recombinant HMGB1 induced mechanical hypersensitivity. Conclusions and Implications: These findings indicate that HMGB1 is involved in the maintenance of nociceptive symptoms in hemi-PD mice via spinal microglial activation. Therefore, central HMGB1 may have potential as a therapeutic target for pain associated with PD.